Clinical Gastroenterology and Hepatology Impact Factor

The headline number is strong, but the more revealing metric here is the JCI of 2.86. That means CGH is performing well above category average after normalization, which matters because gastroenterology contains journals with very different citation cultures.

So the journal is not just coasting on volume or on being tied to the AGA brand. The citation profile says clinicians and researchers are using what gets published here.

The journal's identity matters too. CGH is a clinical-practice journal. A 12.0 JIF in that lane means the journal is rewarding manuscripts that actually change how gastroenterologists and hepatologists read evidence, not just mechanistic GI biology with a clinical sentence bolted on at the end.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 5.19 in 2023 to 5.95 in 2024, and well above the mid-2010s band. That is consistent with CGH's stronger role in contemporary GI practice, especially for translational clinical work, outcomes research, endoscopy, and studies with immediate patient-care relevance.

The key point is that CGH has become harder to treat as a simple second-choice journal. Its own citation profile is strong enough that fit now matters a lot.

The mistake is to see a double-digit JIF and assume CGH is just a lower-significance version of Gastroenterology or Gut.

That is not the cleanest frame. CGH usually rewards papers that are:

• clinically useful now
• focused on GI and liver practice
• strong enough methodologically to change interpretation or management
• written for clinicians rather than primarily for mechanistic readers

That means some papers rejected from a flagship GI journal really do belong here. But some papers that look weaker by prestige logic still do not fit if they are not immediately practice-relevant.

In our pre-submission review work on manuscripts targeting CGH, the recurring misses are usually easy to name after the fact. The authors say the work is clinically important, but the manuscript does not make the practice consequence legible enough for an editor to route it quickly.

CGH tends to reward papers that answer a live GI clinical question in a way readers can actually use.

In our pre-submission review work on manuscripts targeting Clinical Gastroenterology and Hepatology, four failure patterns recur.

The clinical relevance statement is generic. The manuscript says the condition matters, but not what gastroenterologists should do differently after reading the paper.

Single-center evidence is stretched too far. Editors often push back when the paper makes broad practice claims from a narrow cohort without validation or design features that justify the leap.

The study is still more mechanistic than clinical. Good GI biology does not automatically become CGH material if the patient-facing consequence is still indirect.

The manuscript has relevance but not enough decision value. This is common in observational studies that show an association clearly but do not change diagnosis, stratification, treatment, or follow-up.

If that still sounds like the paper, a Clinical Gastroenterology and Hepatology submission readiness check is usually more useful than another round of formatting work.